SAN DIEGO, Feb. 1, 2000 (PRIMEZONE) -- -- Charles Kallmann, chief executive officer and president of Hydrogiene Corporation (OTC BB:HICS.OB), continued today his practice of reporting on a timely basis factual status reports as the Company advances to mid April shipments of its Theraclenze and Mediclenze Personal Hygiene, Water Therapy and Sitz Bath Systems to its first major retail customers.
Status pertaining to the ongoing development of the Company's anti-bacterial "Medigard" product is also subject to the ongoing status report. "Other items of interest will be reported as considered worthy of note", Kallmann stated.
Theraclenze and Mediclenze's tooling is on schedule for deliveries in mid or late March. Plant equipping and setup now in process of installation will enable ramp up of assembly capabilities to 6,000 units on a single shift per day.
Hydrogiene's first National Trade Show will be "Medtrade" in Las Vegas in May 2000 with follow on National Shows in 2000 at the "National Housewares Show" in Chicago and "National Hotel Show" November in New York.
Medigard development with patent filings is now scheduled for April. Medigard will be released for independent laboratory testing in May with Mediclenze and Theraclenze being Medigard coated starting in June 2000.
Activities leading to license of Medigard will commence in April on a National and International effort. Medigard technical data will be available to select inquiries immediately upon patent filing completion. Medigard promises to dramatically change the entire methodology of present state-of-the-art related to disinfecting and killing on long and short-term basis, a wide variety of harmful and potentially fatal viruses through a patented process known as "chemical grafting" to a wide variety of substrates including meats and poultry.
Safe Harbor for Forward-Looking Statements: Except for historical information contained herein, the statements in this news release are forward looking statements that are made pursuant to the Safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ from forecasted results.